PT - JOURNAL ARTICLE AU - AKIMITSU YAMADA AU - KYOKO NAKAZAWA AU - KOHEI AKAZAWA AU - KAZUTAKA NARUI AU - ITARU ENDO AU - YOSHIE HASEGAWA AU - NORIO KOHNO AU - TAKASHI ISHIKAWA AU - THE JONIE STUDY GROUP TI - Impact of the Relative Dose Intensity of Neoadjuvant Chemotherapy With Anthracycline Followed by Taxane on the Survival of Patients With Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: The JONIE1 Study AID - 10.21873/anticanres.14863 DP - 2021 Feb 01 TA - Anticancer Research PG - 1063--1068 VI - 41 IP - 2 4099 - http://ar.iiarjournals.org/content/41/2/1063.short 4100 - http://ar.iiarjournals.org/content/41/2/1063.full SO - Anticancer Res2021 Feb 01; 41 AB - Background/Aim: We evaluated the impact of the relative dose intensity (RDI) of neoadjuvant chemotherapy (NAC) on the survival of patients with breast cancer (BC). Patients and Methods: This randomized phase II trial included 188 patients with human epidermal growth factor receptor 2 (HER2)-negative BC treated with anthracycline followed by paclitaxel as NAC. We grouped patients using a relative dose intensity (RDI) threshold of 85% and evaluated clinicopathological features and clinical outcomes. Results: The 5-year overall survival rate was 91.2% and 76.3%, when RDI ≥85% and <85%, respectively (p=0.015). Age, tumor, and node status, and the RDI were significantly different on univariate analysis, but not on multivariate analysis. An exploratory subgroup analysis revealed that a low RDI was associated with low overall survival of patients with obesity, T1/2 disease, and lymph node metastases. Conclusion: Maintaining the RDI of NAC is crucial for achieving the survival benefit in selected patients with HER2-negative BC.